Mereo BioPharma (MREO)

• Market cap: $294M
• 1 day: 1.65%
• 5 days: 3.35%
• 1 month: 11.45%
• 3 months: -33.45%
• 6 months: -27.17%
• Year to date: -45.91%
• 1 year: -57.86%
• 5 years: -38.33%
• 10 years: -71.54%
• Sector: Healthcare
• Industry: Biotechnology

About: Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Employees: 36

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

148% more call options, than puts

Call options by funds: $8.29M | Put options by funds: $3.35M

58% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 19

48.03% more ownership

Funds ownership: 13.97% [Q1] → 62.0% (+48.03%) [Q2]

7% more capital invested

Capital invested by funds: $250M [Q1] → $267M (+$17.1M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

8% less funds holding

Funds holding: 89 [Q1] → 82 (-7) [Q2]

35% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 17

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5
• Avg. target: $6.5
• High target: $8

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

JP Morgan Priyanka Grover	$8	Overweight Maintained	25 Aug 2025
Needham Gil Blum	$5	Buy Maintained	10 Jul 2025